U.S. markets closed
  • S&P 500

    4,455.48
    +6.50 (+0.15%)
     
  • Dow 30

    34,798.00
    +33.20 (+0.10%)
     
  • Nasdaq

    15,047.70
    -4.50 (-0.03%)
     
  • Russell 2000

    2,248.07
    -10.97 (-0.49%)
     
  • Crude Oil

    73.95
    -0.03 (-0.04%)
     
  • Gold

    1,750.60
    -1.10 (-0.06%)
     
  • Silver

    22.42
    -0.01 (-0.04%)
     
  • EUR/USD

    1.1718
    -0.0029 (-0.25%)
     
  • 10-Yr Bond

    1.4600
    +0.0500 (+3.55%)
     
  • GBP/USD

    1.3667
    -0.0054 (-0.39%)
     
  • USD/JPY

    110.6630
    +0.3620 (+0.33%)
     
  • BTC-USD

    43,539.98
    +782.89 (+1.83%)
     
  • CMC Crypto 200

    1,067.20
    -35.86 (-3.25%)
     
  • FTSE 100

    7,051.48
    -26.87 (-0.38%)
     
  • Nikkei 225

    30,248.81
    +609.41 (+2.06%)
     

Atea Pharma Stock Is Trading Higher As AT-527 Study In COVID-19 Moves Forward With Dosing

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Atea Pharmaceuticals Inc (NASDAQ: AVIR) has dosed the first patient in the Phase 3 MORNINGSKY trial evaluating AT-527 in mild or moderate COVID-19 patients in an outpatient setting.

  • The trial anticipates enrolling approximately 1,400 non-hospitalized adults and adolescents with mild to moderate COVID-19. Enrollment is underway.

  • AT-527 is an orally administered, direct-acting antiviral in development and derived from Atea's purine nucleotide prodrug platform.

  • Under a strategic collaboration, Roche Holdings AG (OTCMKTS: RHHBY) and Atea are jointly developing AT-527 to treat COVID-19.

  • AT-527 targets SARS-CoV-2 ribonucleic acid (RNA) polymerase (nsp12), a highly conserved gene responsible for both viral RNA replication and transcription.

  • The primary endpoint of the trial will measure the time to alleviation or improvement of COVID-19 symptoms. Other efficacy endpoints will include the number of patients requiring medically attended visits or hospitalization for COVID-19.

  • Additionally, the study will also identify and evaluate biomarkers predictive of an antiviral response to AT-527.

  • Price Action: AVIR shares are up 7.65% at $28.69 in the premarket trading on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.